Novartis, an innovative medicines company, announced that the company is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto (sacubitril/valsartan) combination patent.
According to a press release from Novartis, the company will work to appropriately enforce the combination patent through its paediatric exclusivity period expiring in July 2025. It will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto.
There are currently no generic versions of Entresto available in the US.
Novartis is an innovative medicines company. Every day, it work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.
|